Abstract 152P
Background
Till date, intensity-modulated radiation therapy (IMRT) with concurrent chemoradiotherapy (CCRT) and CCRT with standard fractionation three-Dimensional Conformal Radiation Therapy (3D-CRT) have not been compared. In the current study, the outcomes of IMRT-based concurrent chemoradiotherapy (CCRT) and those of 3D-CRT-based CCRT were compared in patients with thoracic esophageal squamous cell carcinoma (TESCC).
Methods
We enrolled 2062 patients with TESCC who had received CCRT and categorized them into two groups based on their treatment modality: group 1 (3D-CRT-based CCRT) and group 2 (IMRT-based CCRT).
Results
The multivariate Cox regression analysis indicated that advanced stages (≥IIIA) of the American Joint Committee on Cancer and 3D-CRT were significant independent predictors of poor outcome in patients with TESCC who received definitive CCRT. Moreover, receiving IMRT-based CCRT (adjusted HR [aHR]: 0.88; 95% confidence interval [CI]: 0.78-0.98) was a significant independent prognostic factor for overall survival (P = .0223). The aHRs (95% CIs) for overall mortality at early (IA-IIB) and advanced clinical stages were 0.91 (0.67-1.25, P = .5746) and 0.88 (0.77-0.99, P = .0368), respectively, in group 2.
Conclusions
IMRT-based CCRT resulted in higher survival rates in the patients with advanced clinical stages IIIA-IIIC TESCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
185P - Evaluation of the effect of cholesorption on the concentration of TNF-α in the serum of the blood in tumours of the biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
186P - Efficacy and safety of sorafenib following hepatic resection in patients with hepatocellular carcinoma: A meta-analysis
Presenter: Yang Yuan
Session: Poster display session
Resources:
Abstract
187P - Correlation between spleenic dose and grade of hematological toxicity in chemoradiation of stomach
Presenter: Umesh Velu
Session: Poster display session
Resources:
Abstract
188P - Survival and prognostic factors in cholangiocarcinoma: A single-center experience
Presenter: Sonngwit Payapwattanawong
Session: Poster display session
Resources:
Abstract
189P - Stereotactic body radiotherapy in primary hepatocellular carcinoma and oligometastatis to liver: A single Institution experience
Presenter: Sayan Paul
Session: Poster display session
Resources:
Abstract
190P - Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
Presenter: Yusuke Nagata
Session: Poster display session
Resources:
Abstract
191P - Assessment of efficacy and safety of sorafenib versus no treatment in Egyptian hepatocellular carcinoma patients
Presenter: Noha El Baghdady
Session: Poster display session
Resources:
Abstract
192P - Clinical importance of the determination of interleukin-6 in bile and blood in tumours of biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
193P - Metastatic carcinoma gall bladder: A clinicoepidemiological profile of Indian patients
Presenter: Anvesh Rathore
Session: Poster display session
Resources:
Abstract
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract